Since clinically observed cognitive symptoms are not always specific to AD [18], a flexible ATN classification system has been developed, including different biomarkers (fluid and imaging) of β-amyloid deposition (A), pathological tau (T), and neurodegeneration (N), where new biomarkers can be added to the three groups [19]. The gene discussed is MAPT; the disease is Alzheimer disease.